Cite
HARVARD Citation
Butzkueven, H. et al. (2018). 085 Clinical outcomes were better for relapsing-remitting multiple sclerosis (RRMS) patients who remained on natalizumab compared to those who switched to oral or injectable therapies after 2 years in the tysabri® observational program (TOP). Journal of neurology, neurosurgery and psychiatry. 89 (6), p. A34. [Online].